2seventy bio, Inc. (TSVT)
NASDAQ: TSVT · Real-Time Price · USD
4.985
+0.005 (0.10%)
Apr 28, 2025, 4:00 PM EDT - Market closed

Company Description

2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States.

The company’s products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma.

It has a collaboration arrangement with Bristol Myers Squibb Company. 2seventy bio, Inc. was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.

2seventy bio, Inc.
2seventy bio logo
Country United States
Founded 2021
Industry Biotechnology
Sector Healthcare
Employees 65
CEO William Baird

Contact Details

Address:
60 Binney Street
Cambridge, Massachusetts 02142
United States
Phone 617 675 7270
Website 2seventybio.com

Stock Details

Ticker Symbol TSVT
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001860782
CUSIP Number 901384107
ISIN Number US9013841070
Employer ID 86-3658454
SIC Code 2834

Key Executives

Name Position
William D. Baird III, M.B.A. Chief Executive Officer, President and Director
Victoria Eatwell Chief Financial Officer
Jessica Snow Chief Operating Officer

Latest SEC Filings

Date Type Title
Apr 28, 2025 10-K/A [Amend] Annual report
Apr 23, 2025 SC 14D9/A Filing
Apr 23, 2025 SC TO-T/A Filing
Apr 17, 2025 SC 14D9/A Filing
Apr 17, 2025 SC TO-T/A Filing
Apr 15, 2025 SCHEDULE 13G Filing
Apr 14, 2025 SC 14D9 Filing
Apr 14, 2025 SC TO-T Filing
Mar 25, 2025 10-K Annual Report
Mar 25, 2025 8-K Current Report